Aclarion (ACON) Set to Announce Earnings on Wednesday

Aclarion (NASDAQ:ACON) is projected to release its Q3 2026 results before the market opens on Wednesday, November 11th. Analysts expect Aclarion to announce earnings of ($1.15) per share and revenue of $0.03 million for the quarter. Interested persons may visit the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Friday, November 6, 2026 at 12:30 PM ET.

Aclarion (NASDAQ:ACON) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($1.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.05) by ($0.07). Aclarion had a negative return on equity of 59.34% and a negative net margin of 10,948.81%. The company had revenue of $0.03 million during the quarter, compared to analysts’ expectations of $0.03 million. On average, analysts expect Aclarion to post ($4.51) EPS for the current fiscal year and ($5.37) EPS for the next fiscal year.

Aclarion Stock Performance

Shares of ACON opened at $1.76 on Wednesday. The company’s 50 day moving average price is $2.29 and its 200 day moving average price is $2.84. Aclarion has a 52 week low of $1.71 and a 52 week high of $9.36. The company has a market capitalization of $5.07 million, a PE ratio of -0.24 and a beta of 1.21.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Aclarion in a research note on Tuesday. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $7.50.

Insiders Place Their Bets

In other news, Director Ryan Bond purchased 21,122 shares of the business’s stock in a transaction dated Thursday, August 13th. The stock was bought at an average cost of $2.37 per share, with a total value of $50,059.14. Following the purchase, the director directly owned 76,122 shares of the company’s stock, valued at approximately $180,409.14. This trade represents a 38.40% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Over the last quarter, insiders bought 51,863 shares of company stock valued at $125,670. Corporate insiders own 0.01% of the company’s stock.

About Aclarion

Aclarion, Inc is a medical technology company focused on improving the diagnosis and treatment of chronic low back pain. The company develops data-driven tools intended to help physicians identify the spinal discs most likely to be contributing to a patient’s pain and support more informed treatment decisions.

Its principal product is Nociscan, a cloud-based software platform that analyzes magnetic resonance spectroscopy data from the spine. Using proprietary algorithms and chemical biomarkers associated with disc degeneration, Nociscan is designed to provide information about disc health and help distinguish potentially painful discs from discs that may not be the primary source of symptoms.

Aclarion’s technology is intended for use by spine specialists, radiologists and other healthcare providers as an adjunct to conventional imaging and clinical evaluation.